Mark A. Feitelson

8.8k total citations · 3 hit papers
124 papers, 6.2k citations indexed

About

Mark A. Feitelson is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Mark A. Feitelson has authored 124 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Epidemiology, 53 papers in Hepatology and 45 papers in Molecular Biology. Recurrent topics in Mark A. Feitelson's work include Hepatitis B Virus Studies (84 papers), Hepatitis C virus research (47 papers) and Liver Disease Diagnosis and Treatment (33 papers). Mark A. Feitelson is often cited by papers focused on Hepatitis B Virus Studies (84 papers), Hepatitis C virus research (47 papers) and Liver Disease Diagnosis and Treatment (33 papers). Mark A. Feitelson collaborates with scholars based in United States, China and South Africa. Mark A. Feitelson's co-authors include Alla Arzumanyan, Helena Reis, Karl Münger, Enrique A. Mesri, Zhaorui Lian, Jingbo Pan, Marcia M. Clayton, Bill Sun, Lifeng Duan and Xin Wei Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Mark A. Feitelson

124 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

2013 643 citations Alla Arzumanyan, Mark A. Feitelson et al. profile →
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

1994 563 citations Mark A. Feitelson et al. profile →
Human Viral Oncogenesis: A Cancer Hallmarks Analysis

2014 473 citations Mark A. Feitelson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Feitelson United States	41	3.5k	2.6k	2.1k	1.5k	1.1k	124	6.2k
Yosef Shaul Israel	52	3.1k 0.9×	5.6k 2.2×	1.3k 0.6×	2.0k 1.3×	721 0.7×	143	8.7k
Robert Steele United States	43	1.7k 0.5×	2.3k 0.9×	1.8k 0.9×	734 0.5×	1.3k 1.2×	83	5.0k
Hiroyuki Marusawa Japan	43	2.4k 0.7×	2.9k 1.1×	2.0k 0.9×	1.5k 1.0×	1.3k 1.2×	160	7.1k
Jing‐hsiung James Ou United States	44	4.3k 1.2×	2.9k 1.1×	2.6k 1.2×	512 0.3×	475 0.4×	100	7.6k
Bruno Sáinz Spain	39	1.1k 0.3×	2.0k 0.8×	620 0.3×	1.7k 1.1×	1.1k 1.0×	88	4.7k
David A. Shafritz United States	52	3.6k 1.0×	3.4k 1.3×	4.9k 2.3×	911 0.6×	304 0.3×	145	9.7k
Christine Neuveut France	31	1.4k 0.4×	2.0k 0.8×	810 0.4×	456 0.3×	344 0.3×	53	3.9k
Liang‐Guo Xu China	29	1.0k 0.3×	2.1k 0.8×	798 0.4×	695 0.4×	1.0k 0.9×	63	5.1k
Satoshi Ishido Japan	36	1.6k 0.4×	2.2k 0.9×	641 0.3×	955 0.6×	247 0.2×	94	5.1k
Shiu‐Wan Chan United Kingdom	20	2.2k 0.6×	939 0.4×	2.4k 1.1×	383 0.2×	194 0.2×	37	3.9k

Countries citing papers authored by Mark A. Feitelson

Since Specialization

Citations

This map shows the geographic impact of Mark A. Feitelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Feitelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Feitelson more than expected).

Fields of papers citing papers by Mark A. Feitelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Feitelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Feitelson. The network helps show where Mark A. Feitelson may publish in the future.

Co-authorship network of co-authors of Mark A. Feitelson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Feitelson. A scholar is included among the top collaborators of Mark A. Feitelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Feitelson. Mark A. Feitelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arzumanyan, Alla, et al.. (2021). Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia. 23(5). 529–538. 49 indexed citations

Feitelson, Mark A.. (2016). Can we stop the progression of chronic liver disease to hepatocellular carcinoma. Translational Cancer Research. 5(4). 1 indexed citations

Arzumanyan, Alla, Vaishnavi Sambandam, Marcia M. Clayton, et al.. (2012). Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein. Cancer Research. 72(22). 5912–5920. 58 indexed citations

Wang, Wen, Lan‐Juan Zhao, Yan Wang, et al.. (2012). Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomarkers. 11(1). 29–39. 13 indexed citations

Yuan, Ke, Zhaorui Lian, Bill Sun, et al.. (2012). Role of miR-148a in Hepatitis B Associated Hepatocellular Carcinoma. PLoS ONE. 7(4). e35331–e35331. 82 indexed citations

Arzumanyan, Alla, et al.. (2011). Does the Hepatitis B Antigen HBx Promote the Appearance of Liver Cancer Stem Cells?. Cancer Research. 71(10). 3701–3708. 96 indexed citations

Fan, Rui, Xiaohua Li, Xue Zou, et al.. (2010). Adenoviral‐mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. International Journal of Cancer. 128(12). 2980–2993. 12 indexed citations

Liu, Xiaohong, Shuhui Zhang, Shunmin Zhang, et al.. (2008). Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochemical and Biophysical Research Communications. 373(4). 643–647. 17 indexed citations

Liao, Xiaoling, Hao Ren, Ping Zhao, et al.. (2007). Efficient Induction of Mouse Immune Responses to Hepatitis C Virus by Viral Core Protein-Carrying Attenuated Salmonella typhimurium. Viral Immunology. 20(3). 469–478. 4 indexed citations

10.

Lian, Zhaorui, Jie Liu, Li Li, et al.. (2006). Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of β-catenin. Hepatology. 43(3). 415–424. 52 indexed citations

11.

Strayer, David S., Mark A. Feitelson, Bill Sun, & Alexey A. Matskevich. (2005). Paradigms for Conditional Expression of RNA Interference Molecules for Use Against Viral Targets. Methods in enzymology on CD-ROM/Methods in enzymology. 392. 227–241. 7 indexed citations

12.

Feitelson, Mark A., Jonathan Larkin, & Raymond F. Schinazi. (2004). Hepatitis B Virus Transgenic Severe Combined Immunodeficient Mouse Model of Acute and Chronic Liver Disease. Humana Press eBooks. 96. 269–288. 1 indexed citations

13.

Lian, Zhaorui, Jie Liu, Li Li, et al.. (2003). Upregulated Expression of a Unique Gene by Hepatitis B x Antigen Promotes Hepatocellular Growth and Tumorigenesis. Neoplasia. 5(3). 229–244. 33 indexed citations

14.

Feitelson, Mark A.. (2001). Chronic hepatitis C virus infection and the pathogenesis of hepatocellular carcinoma.. PubMed. 49 Suppl 2. S65–74. 2 indexed citations

15.

Lian, Zhaorui, Jie Liu, Jingbo Pan, et al.. (2001). A Cellular Gene Up–Regulated by Hepatitis B Virus-Encoded X Antigen Promotes Hepatocellular Growth and Survival. Hepatology. 34(1). 146–157. 44 indexed citations

16.

Lian, Zhaorui, et al.. (2000). Identification of differentially expressed genes in HBxAg transfected HepG2 cells by suppression subtractive hybridization. Zhonghua xiaohua zazhi. 20(3). 159–162. 1 indexed citations

17.

Feitelson, Mark A.. (1998). Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery. 5(4). 367–374. 11 indexed citations

18.

Wang, Wenliang, Thomas London, Laura Lega, & Mark A. Feitelson. (1991). HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology. 14(1). 29–37. 91 indexed citations

19.

Feitelson, Mark A., et al.. (1990). Monoclonal antibodies raised to purified woodchuck hepatitis virus core antigen particles demonstrate X antigen reactivity. Virology. 177(1). 357–366. 16 indexed citations

20.

Feitelson, Mark A., et al.. (1988). Presence of antibodies to the polymerase gene product(s) of hepatitis B and woodchuck hepatitis virus in natural and experimental infections. Journal of Medical Virology. 24(2). 121–136. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact